News - Page 11

With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion plans that are aimed, at least in part, at abating the

As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai Immunotherapeutics.

Stada will invest more than 85 million euros (around $101 million) to build a new production facility in Saudi Arabia, which will ultimately serve as a supply hub for the broader Middle

The clamor for radioisotopes has continued into the new year, with Novartis inking a deal with radiopharmaceutical producer Niowave to supply the pharma giant with the specialized ingredient Actinium-225 (Ac-225) used to

Novo plans to invest in an expansion of its facility in Athlone, Ireland, to produce its Wegovy pill for markets beyond the U.S., the company’s CEO, Mike Doustdar, told Bloomberg News in

PharmaEssentia will spend $46 million to build a manufacturing facility in Puerto Rico. The move forms part of the Taiwanese biotech’s global expansion strategy to support demand for its rare blood disease

The agreement includes mRNA vaccine supply and a technology transfer that allows Mexico’s Laboratorios Liomont to produce Moderna’s 2025-2026 COVID vaccine.

The agreement will see Phlow as the first drugmaker to produce epinephrine injection API in the U.S., while Fresenius will work on formulation and finished doses to ship to U.S. hospitals and

OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giant’s CAR-T programs.

Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus, with a big boost from its government. The country will invest 100 billion rupees ($1.1 billion)